{"id":4028,"date":"2019-11-20T19:57:13","date_gmt":"2019-11-20T16:27:13","guid":{"rendered":"https:\/\/cedalco.com\/project\/%d8%af%d9%88%d8%b3%d8%aa%d8%a7%da%a9%d8%b3%d9%84\/"},"modified":"2026-01-09T22:16:45","modified_gmt":"2026-01-09T18:46:45","slug":"docetaxel","status":"publish","type":"dt_portfolio","link":"https:\/\/cedalco.com\/en\/project\/docetaxel\/","title":{"rendered":"TeoTaxol"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-post\" data-elementor-id=\"4028\" class=\"elementor elementor-4028 elementor-112\" data-elementor-post-type=\"dt_portfolio\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-ab6c1af elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"ab6c1af\" data-element_type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-fe7a2b2\" data-id=\"fe7a2b2\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-inner-section elementor-element elementor-element-b4b511c elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"b4b511c\" data-element_type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-50 elementor-inner-column elementor-element elementor-element-aa9a73c\" data-id=\"aa9a73c\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-016e0a3 elementor-widget elementor-widget-image\" data-id=\"016e0a3\" data-element_type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t<figure class=\"wp-caption\">\n\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/cedalco.com\/wp-content\/uploads\/2019\/11\/teotaxel.jpg\" data-elementor-open-lightbox=\"yes\" data-elementor-lightbox-title=\"teotaxel\" data-e-action-hash=\"#elementor-action%3Aaction%3Dlightbox%26settings%3DeyJpZCI6NzgwMCwidXJsIjoiaHR0cHM6XC9cL2NlZGFsY28uY29tXC93cC1jb250ZW50XC91cGxvYWRzXC8yMDE5XC8xMVwvdGVvdGF4ZWwuanBnIn0%3D\">\n\t\t\t\t\t\t\t<img fetchpriority=\"high\" decoding=\"async\" width=\"800\" height=\"800\" src=\"https:\/\/cedalco.com\/wp-content\/uploads\/2019\/11\/teotaxel.jpg\" class=\"elementor-animation-float attachment-full size-full wp-image-7800\" alt=\"\" srcset=\"https:\/\/cedalco.com\/wp-content\/uploads\/2019\/11\/teotaxel.jpg 800w, https:\/\/cedalco.com\/wp-content\/uploads\/2019\/11\/teotaxel-300x300.jpg 300w, https:\/\/cedalco.com\/wp-content\/uploads\/2019\/11\/teotaxel-150x150.jpg 150w, https:\/\/cedalco.com\/wp-content\/uploads\/2019\/11\/teotaxel-768x768.jpg 768w\" sizes=\"(max-width: 800px) 100vw, 800px\" title=\"\">\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<figcaption class=\"widget-image-caption wp-caption-text\">Click on the photo to enlarge <i class=\"fa fa-search-plus\" aria-hidden=\"true\"><\/i><\/figcaption>\n\t\t\t\t\t\t\t\t\t\t<\/figure>\n\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t<div class=\"elementor-column elementor-col-50 elementor-inner-column elementor-element elementor-element-34e1e73\" data-id=\"34e1e73\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-f318958 elementor-widget__width-auto elementor-widget-mobile__width-inherit elementor-widget elementor-widget-theme-post-title elementor-page-title elementor-widget-heading\" data-id=\"f318958\" data-element_type=\"widget\" data-widget_type=\"theme-post-title.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t<h1 class=\"elementor-heading-title elementor-size-default\">TeoTaxol<sup>\u00ae<\/sup><\/h1>\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-e0678ee elementor-widget__width-auto elementor-widget elementor-widget-text-editor\" data-id=\"e0678ee\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<p>DMF: <span style=\"text-decoration: underline;\"><strong>26580<\/strong><\/span><\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-9605032 elementor-widget elementor-widget-spacer\" data-id=\"9605032\" data-element_type=\"widget\" data-widget_type=\"spacer.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<div class=\"elementor-spacer\">\n\t\t\t<div class=\"elementor-spacer-inner\"><\/div>\n\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-22a0968 content-align-mobile-left elementor-widget__width-initial elementor-widget-mobile__width-inherit icon-box-vertical-align-top icon-position-left icon-vertical-align-start elementor-widget elementor-widget-the7_icon_box_widget\" data-id=\"22a0968\" data-element_type=\"widget\" data-widget_type=\"the7_icon_box_widget.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\n\t\t<div class=\"the7-box-wrapper the7-elementor-widget the7_icon_box_widget-22a0968\">\t\t\t<div class=\"box-content-wrapper\">\n\t\t\t\t\t\t\t\t\t<a class=\"elementor-icon-div\" >\t\t\t\t\t\t<div class=\"elementor-icon\">\n\t\t\t\t\t\t\t<i aria-hidden=\"true\" class=\"fas fa-circle-notch\"><\/i>\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/a>\t\t\t\t\t\t\t\t<div class=\"box-content\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h4 class=\"box-heading\">\n\t\t\t\t\t\t\t<a >\t\t\t\t\t\t\t\tGeneric Name\t\t\t\t\t\t\t<\/a>\t\t\t\t\t\t<\/h4>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"box-description\">Docetaxel<\/div>\n\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-cfb052f content-align-mobile-left elementor-widget__width-initial elementor-widget-mobile__width-inherit icon-box-vertical-align-top icon-position-left icon-vertical-align-start elementor-widget elementor-widget-the7_icon_box_widget\" data-id=\"cfb052f\" data-element_type=\"widget\" data-widget_type=\"the7_icon_box_widget.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\n\t\t<div class=\"the7-box-wrapper the7-elementor-widget the7_icon_box_widget-cfb052f\">\t\t\t<div class=\"box-content-wrapper\">\n\t\t\t\t\t\t\t\t\t<a class=\"elementor-icon-div\" >\t\t\t\t\t\t<div class=\"elementor-icon\">\n\t\t\t\t\t\t\t<i aria-hidden=\"true\" class=\"fas fa-circle-notch\"><\/i>\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/a>\t\t\t\t\t\t\t\t<div class=\"box-content\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h4 class=\"box-heading\">\n\t\t\t\t\t\t\t<a >\t\t\t\t\t\t\t\tBrand Name\t\t\t\t\t\t\t<\/a>\t\t\t\t\t\t<\/h4>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"box-description\"><sup>\u00ae<\/sup>Teotaxol<\/div>\n\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-c8ff444 elementor-widget__width-initial elementor-widget-mobile__width-inherit content-align-mobile-left icon-box-vertical-align-top icon-position-left icon-vertical-align-start elementor-widget elementor-widget-the7_icon_box_widget\" data-id=\"c8ff444\" data-element_type=\"widget\" data-widget_type=\"the7_icon_box_widget.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\n\t\t<div class=\"the7-box-wrapper the7-elementor-widget the7_icon_box_widget-c8ff444\">\t\t\t<div class=\"box-content-wrapper\">\n\t\t\t\t\t\t\t\t\t<a class=\"elementor-icon-div\" >\t\t\t\t\t\t<div class=\"elementor-icon\">\n\t\t\t\t\t\t\t<i aria-hidden=\"true\" class=\"fas fa-circle-notch\"><\/i>\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/a>\t\t\t\t\t\t\t\t<div class=\"box-content\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h4 class=\"box-heading\">\n\t\t\t\t\t\t\t<a >\t\t\t\t\t\t\t\tDrug Class\t\t\t\t\t\t\t<\/a>\t\t\t\t\t\t<\/h4>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"box-description\">Mitotic inhibitors<\/div>\n\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-1e9d9c3 elementor-widget__width-initial elementor-widget-mobile__width-inherit content-align-mobile-left icon-box-vertical-align-top icon-position-left icon-vertical-align-start elementor-widget elementor-widget-the7_icon_box_widget\" data-id=\"1e9d9c3\" data-element_type=\"widget\" data-widget_type=\"the7_icon_box_widget.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\n\t\t<div class=\"the7-box-wrapper the7-elementor-widget the7_icon_box_widget-1e9d9c3\">\t\t\t<div class=\"box-content-wrapper\">\n\t\t\t\t\t\t\t\t\t<a class=\"elementor-icon-div\" >\t\t\t\t\t\t<div class=\"elementor-icon\">\n\t\t\t\t\t\t\t<i aria-hidden=\"true\" class=\"fas fa-circle-notch\"><\/i>\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/a>\t\t\t\t\t\t\t\t<div class=\"box-content\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h4 class=\"box-heading\">\n\t\t\t\t\t\t\t<a >\t\t\t\t\t\t\t\tDosage Form\t\t\t\t\t\t\t<\/a>\t\t\t\t\t\t<\/h4>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"box-description\">Concentrate for solution for infusion 20 and 80 mg <\/div>\n\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<div class=\"elementor-element elementor-element-a998ecf the7-e-tabs-view-vertical icon-align-left elementor-widget elementor-widget-the7-tabs\" data-id=\"a998ecf\" data-element_type=\"widget\" data-settings=\"{&quot;accordion_breakpoint&quot;:&quot;mobile&quot;}\" data-widget_type=\"the7-tabs.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t<div class=\"the7-e-tabs-wrapper\">\n\t\t<div class=\"the7-e-tabs-nav-wrapper\">\n\t\t\t<div class=\"the7-e-tabs-nav-scroll-wrapper\">\n\t\t\t\t<div class=\"the7-e-tabs-nav\" role=\"tablist\">\n\t\t\t\t\t\t\t\t\t\t<span class=\"item-divider\" aria-hidden=\"true\"><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t<div id=\"the7-e-tab-title-1771\" class=\"the7-e-tab-title\" aria-selected=\"true\" data-tab=\"1\" role=\"tab\" tabindex=\"0\" aria-controls=\"the7-e-tab-content-1771\" aria-expanded=\"false\">\n\t\t\t\t\t\t\t\t\t\t<span class=\"the7-e-tab-icon elementor-icon\" aria-hidden=\"true\"><i class=\"fas fa-virus\"><\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t<h5 class=\"the7-e-tab-title-text\">\n\t\t\t\t\t\t\tIndications\t\t\t\t\t\t\t<\/h5>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<span class=\"item-divider\" aria-hidden=\"true\"><\/span>\n\t\t\t\t\t\t\t\t\t\t\t<div id=\"the7-e-tab-title-1772\" class=\"the7-e-tab-title\" aria-selected=\"false\" data-tab=\"2\" role=\"tab\" tabindex=\"-1\" aria-controls=\"the7-e-tab-content-1772\" aria-expanded=\"false\">\n\t\t\t\t\t\t\t\t\t\t<span class=\"the7-e-tab-icon elementor-icon\" aria-hidden=\"true\"><i class=\"fas fa-virus-slash\"><\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t<h5 class=\"the7-e-tab-title-text\">\n\t\t\t\t\t\t\tContradications\t\t\t\t\t\t\t<\/h5>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<span class=\"item-divider\" aria-hidden=\"true\"><\/span>\n\t\t\t\t\t\t\t\t\t\t\t<div id=\"the7-e-tab-title-1773\" class=\"the7-e-tab-title\" aria-selected=\"false\" data-tab=\"3\" role=\"tab\" tabindex=\"-1\" aria-controls=\"the7-e-tab-content-1773\" aria-expanded=\"false\">\n\t\t\t\t\t\t\t\t\t\t<span class=\"the7-e-tab-icon elementor-icon\" aria-hidden=\"true\"><i class=\"fas fa-list-ul\"><\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t<h5 class=\"the7-e-tab-title-text\">\n\t\t\t\t\t\t\tWarnings and Precautions\t\t\t\t\t\t\t<\/h5>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<span class=\"item-divider\" aria-hidden=\"true\"><\/span>\n\t\t\t\t\t\t\t\t\t\t\t<div id=\"the7-e-tab-title-1774\" class=\"the7-e-tab-title\" aria-selected=\"false\" data-tab=\"4\" role=\"tab\" tabindex=\"-1\" aria-controls=\"the7-e-tab-content-1774\" aria-expanded=\"false\">\n\t\t\t\t\t\t\t\t\t\t<span class=\"the7-e-tab-icon elementor-icon\" aria-hidden=\"true\"><i class=\"fas fa-list-ul\"><\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t<h5 class=\"the7-e-tab-title-text\">\n\t\t\t\t\t\t\tDosage & Administration\t\t\t\t\t\t\t<\/h5>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<span class=\"item-divider\" aria-hidden=\"true\"><\/span>\n\t\t\t\t\t\t\t\t\t\t\t<div id=\"the7-e-tab-title-1775\" class=\"the7-e-tab-title\" aria-selected=\"false\" data-tab=\"5\" role=\"tab\" tabindex=\"-1\" aria-controls=\"the7-e-tab-content-1775\" aria-expanded=\"false\">\n\t\t\t\t\t\t\t\t\t\t<span class=\"the7-e-tab-icon elementor-icon\" aria-hidden=\"true\"><i class=\"far fa-bell\"><\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t<h5 class=\"the7-e-tab-title-text\">\n\t\t\t\t\t\t\tAdverse Reactions\t\t\t\t\t\t\t<\/h5>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<span class=\"item-divider\" aria-hidden=\"true\"><\/span>\n\t\t\t\t\t\t\t\t\t\t\t<div id=\"the7-e-tab-title-1776\" class=\"the7-e-tab-title\" aria-selected=\"false\" data-tab=\"6\" role=\"tab\" tabindex=\"-1\" aria-controls=\"the7-e-tab-content-1776\" aria-expanded=\"false\">\n\t\t\t\t\t\t\t\t\t\t<span class=\"the7-e-tab-icon elementor-icon\" aria-hidden=\"true\"><i class=\"fab fa-confluence\"><\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t<h5 class=\"the7-e-tab-title-text\">\n\t\t\t\t\t\t\tDrug Interactions\t\t\t\t\t\t\t<\/h5>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<span class=\"item-divider\" aria-hidden=\"true\"><\/span>\n\t\t\t\t\t\t\t\t\t\t\t<div id=\"the7-e-tab-title-1777\" class=\"the7-e-tab-title\" aria-selected=\"false\" data-tab=\"7\" role=\"tab\" tabindex=\"-1\" aria-controls=\"the7-e-tab-content-1777\" aria-expanded=\"false\">\n\t\t\t\t\t\t\t\t\t\t<span class=\"the7-e-tab-icon elementor-icon\" aria-hidden=\"true\"><i class=\"fas fa-baby\"><\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t<h5 class=\"the7-e-tab-title-text\">\n\t\t\t\t\t\t\t Pregnancy and Lactation\t\t\t\t\t\t\t<\/h5>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<span class=\"item-divider\" aria-hidden=\"true\"><\/span>\n\t\t\t\t\t\t\t\t\t\t\t<div id=\"the7-e-tab-title-1778\" class=\"the7-e-tab-title\" aria-selected=\"false\" data-tab=\"8\" role=\"tab\" tabindex=\"-1\" aria-controls=\"the7-e-tab-content-1778\" aria-expanded=\"false\">\n\t\t\t\t\t\t\t\t\t\t<span class=\"the7-e-tab-icon elementor-icon\" aria-hidden=\"true\"><i class=\"fas fa-box\"><\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t<h5 class=\"the7-e-tab-title-text\">\n\t\t\t\t\t\t\tStorage Conditions\t\t\t\t\t\t\t<\/h5>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<span class=\"item-divider\" aria-hidden=\"true\"><\/span>\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t\t<div class=\"the7-e-tab-nav-button left-button\"><\/div>\n\t\t\t<div class=\"the7-e-tab-nav-button right-button\"><\/div>\n\t\t<\/div>\n\t\t<div class=\"the7-e-tabs-content\" role=\"tablist\" aria-orientation=\"vertical\">\n\t\t\t<span class=\"item-divider\" aria-hidden=\"true\"><\/span>\n\t\t\t\t\t\t\t<div class=\"the7-e-tab-item-wrapper\" data-tab=\"1\">\n\t\t\t\t\t<div class=\"the7-e-tab-title\" aria-selected=\"true\" data-tab=\"1\" role=\"tab\" tabindex=\"0\" aria-controls=\"elementor-tab-content-1771\" aria-expanded=\"false\">\n\t\t\t\t\t\t\t\t\t<span class=\"the7-e-tab-icon elementor-icon\" aria-hidden=\"true\"><i class=\"fas fa-virus\"><\/i><\/span>\n\t\t\t\t\t\t\t\t\t<h5 class=\"the7-e-tab-title-text\">\n\t\t\t\t\t\t\tIndications\t\t\t\t\t\t<\/h5>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t<div id=\"the7-e-tab-content-1771\" class=\"the7-e-tab-content the7-e-tab-text-content\" data-tab=\"1\" role=\"tabpanel\" aria-labelledby=\"the7-e-tab-title-1771\" tabindex=\"0\" hidden=\"false\"><ul><li><strong>Breast Cancer<\/strong><\/li><\/ul><p>Teotaxol\u00ae is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Teotaxol\u00ae in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer.<\/p><ul><li><strong>Non-Small Cell Lung Cancer<\/strong><\/li><\/ul><p>Teotaxol\u00ae as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. Teotaxol\u00ae in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition.<\/p><ul><li><strong>Prostate Cancer <\/strong><\/li><\/ul><p>Teotaxol\u00ae in combination with prednisone is indicated for the treatment of patients with androgen independent (hormone refractory) metastatic prostate cancer.<\/p><ul><li><strong>Gastric Adenocarcinoma<\/strong><\/li><\/ul><p>Teotaxol\u00ae in combination with cisplatin and fluorouracil is indicated for the treatment of patients with advanced gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for advanced disease.<\/p><ul><li><strong>Head and Neck Cancer<\/strong><\/li><\/ul><p>Teotaxol\u00ae in combination with cisplatin and fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head<\/p><p>and neck (SCCHN).<\/p><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<span class=\"item-divider\" aria-hidden=\"true\"><\/span>\n\t\t\t\t\t\t\t<div class=\"the7-e-tab-item-wrapper\" data-tab=\"2\">\n\t\t\t\t\t<div class=\"the7-e-tab-title\" aria-selected=\"false\" data-tab=\"2\" role=\"tab\" tabindex=\"-1\" aria-controls=\"elementor-tab-content-1772\" aria-expanded=\"false\">\n\t\t\t\t\t\t\t\t\t<span class=\"the7-e-tab-icon elementor-icon\" aria-hidden=\"true\"><i class=\"fas fa-virus-slash\"><\/i><\/span>\n\t\t\t\t\t\t\t\t\t<h5 class=\"the7-e-tab-title-text\">\n\t\t\t\t\t\t\tContradications\t\t\t\t\t\t<\/h5>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t<div id=\"the7-e-tab-content-1772\" class=\"the7-e-tab-content the7-e-tab-text-content\" data-tab=\"2\" role=\"tabpanel\" aria-labelledby=\"the7-e-tab-title-1772\" tabindex=\"0\" hidden=\"hidden\"><ul><li>Patients who have a history of severe hypersensitivity reactions to docetaxel or to other drugs containing polysorbate 80, ethanol anhydrous, citric acid<\/li><li>Patients with baseline neutrophil count of &lt; 1,500 cells\/mm<sup>3<\/sup>.<\/li><li>Patients with severe liver impairment<\/li><li>Pregnancy and lactation<\/li><\/ul><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<span class=\"item-divider\" aria-hidden=\"true\"><\/span>\n\t\t\t\t\t\t\t<div class=\"the7-e-tab-item-wrapper\" data-tab=\"3\">\n\t\t\t\t\t<div class=\"the7-e-tab-title\" aria-selected=\"false\" data-tab=\"3\" role=\"tab\" tabindex=\"-1\" aria-controls=\"elementor-tab-content-1773\" aria-expanded=\"false\">\n\t\t\t\t\t\t\t\t\t<span class=\"the7-e-tab-icon elementor-icon\" aria-hidden=\"true\"><i class=\"fas fa-list-ul\"><\/i><\/span>\n\t\t\t\t\t\t\t\t\t<h5 class=\"the7-e-tab-title-text\">\n\t\t\t\t\t\t\tWarnings and Precautions\t\t\t\t\t\t<\/h5>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t<div id=\"the7-e-tab-content-1773\" class=\"the7-e-tab-content the7-e-tab-text-content\" data-tab=\"3\" role=\"tabpanel\" aria-labelledby=\"the7-e-tab-title-1773\" tabindex=\"0\" hidden=\"hidden\"><p><strong>Toxic Deaths<\/strong><\/p><p>There are cases of toxic deaths after treatment with docetaxel in Breast cancer and non-small cell lung cancer<\/p><p><strong>Hepatic Impairment<\/strong><\/p><p>Patients with combined abnormalities of transaminases and alkaline phosphatase should not be treated with Teotaxol\u00ae<\/p><p><strong>Hematologic Effects<\/strong><\/p><p>Perform frequent peripheral blood cell counts on all patients receiving Teotaxol\u00ae. Patients should not be retreated with subsequent cycles of Teotaxol\u00ae until neutrophils recover to a level &gt;1500 cells\/mm<sup>3<\/sup> and platelets recover to a level &gt; 100,000 cells\/mm<sup>3<\/sup>. A 25% reduction in the dose of Teotaxol\u00ae is recommended during subsequent cycles following severe neutropenia (&lt;500 cells\/mm<sup>3<\/sup>) lasting 7 days or more, febrile neutropenia, or a grade 4 infection in a Teotaxol\u00ae cycle.<\/p><p>Neutropenia (&lt;2000 neutrophils\/mm<sup>3<\/sup>) occurs in virtually all patients given 60 mg\/m<sup>2<\/sup> to 100 mg\/m<sup>2<\/sup> of docetaxel and grade 4 neutropenia (&lt;500 cells\/mm<sup>3<\/sup>) occurs in 85% of patients given 100 mg\/m<sup>2<\/sup> and 75% of patients given 60 mg\/m<sup>2<\/sup>. Frequent monitoring of blood counts is, therefore, essential so that dose can be adjusted. Teotaxol\u00ae should not be administered to patients with neutrophils &lt;1500 cells\/mm<sup>3<\/sup>. Febrile neutropenia occurred in about 12% of patients given 100 mg\/m<sup>2<\/sup> but was very uncommon in patients given 60 mg\/m<sup>2<\/sup>. Hematologic responses, febrile reactions and infections, and rates of septic death for different regimens are dose related<\/p><p>Three breast cancer patients with severe liver impairment (bilirubin &gt;1.7 times ULN) developed fatal gastrointestinal bleeding associated with severe drug-induced thrombocytopenia. In gastric cancer patients treated with docetaxel in combination with cisplatin and fluorouracil (TCF), febrile neutropenia and\/or neutropenic infection occurred in 12% of patients receiving G-CSF compared to 28% who did not. Patients receiving TCF should be closely monitored during the first and subsequent cycles for febrile neutropenia and neutropenic infection<\/p><p><strong>Hypersensitivity Reactions<\/strong><\/p><p>Patients should be observed closely for hypersensitivity reactions, especially during the first and second infusions. Severe hypersensitivity reactions characterized by generalized rash\/erythema, hypotension and\/or bronchospasm, or very rarely fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. Severe hypersensitivity reactions require immediate discontinuation of the Teotaxol\u00ae infusion and aggressive therapy. Patients with a history of severe hypersensitivity reactions should not be rechallenged with Teotaxol\u00ae. Hypersensitivity reactions may occur within a few minutes following initiation of a Teotaxol\u00ae infusion. If minor reactions such as flushing or localized skin reactions occur, interruption of therapy is not required. All patients should be premedicated with an oral corticosteroid prior to the initiation of the infusion of Teotaxol\u00ae<\/p><p><strong>Fluid Retention<\/strong><\/p><p>Severe fluid retention has been reported following docetaxel therapy. Patients should be premedicated with oral corticosteroids prior to each Teotaxol\u00ae administration to reduce the incidence and severity of fluid retention<\/p><p>Patients with pre-existing effusions should be closely monitored from the first dose for the possible exacerbation of the effusions.<\/p><p>When fluid retention occurs, peripheral edema usually starts in the lower extremities and may become generalized with a median weight gain of 2 kg.<\/p><p>Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s).<\/p><p><strong>Acute Myeloid Leukemia<\/strong><\/p><p>Treatment-related acute myeloid leukemia (AML) or myelodysplasia has occurred in patients given anthracyclines and\/or cyclophosphamide, including use in adjuvant therapy for breast cancer. In TAC-treated patients(patients who received fluorouracil, doxorubicin and cyclophosphamide), the risk of delayed myelodysplasia or myeloid leukemia requires hematological follow-up.<\/p><p><strong>Cutaneous Reactions<\/strong><\/p><p>Localized erythema of the extremities with edema followed by desquamation has been observed. In case of severe skin toxicity, an adjustment in dosage is recommended.<\/p><p><strong>Neurologic Reactions<\/strong><\/p><p>Severe neurosensory symptoms (e.g. paresthesia, dysesthesia, pain) were observed in metastatic breast cancer patients treated with docetaxel. When these symptoms occur, dosage must be adjusted. If symptoms persist, treatment should be discontinued.<\/p><p><strong>Asthenia<\/strong><\/p><p>Severe asthenia has been reported in some metastatic breast cancer patients and it has led to treatment discontinuation in some of them. Symptoms of fatigue and weakness may last a few days up to several weeks and may be associated with deterioration of performance status in patients with progressive disease.<\/p><p><strong>Respiratory disorders<\/strong><\/p><p>Acute respiratory distress syndrome, interstitial pneumonia\/pneumonitis, interstitial lung disease, pulmonary fibrosis and respiratory failure have been reported and may be associated with fatal outcome. Cases of radiation pneumonitis have been reported in patients receiving concomitant radiotherapy. If new or worsening pulmonary symptoms develop, patients should be closely monitored, promptly investigated, and appropriately treated. Interruption of Teotaxol\u00ae therapy is recommended until diagnosis is available. Early use of supportive care measures may help improve the condition. The benefit of resuming Teotaxol\u00ae treatment must be carefully evaluated.<\/p><p><strong>Cardiac toxicity<\/strong><\/p><p>Heart failure has been observed in patients receiving docetaxel in combination with trastuzumab, particularly following anthracycline (doxorubicin or epirubicin)\u00adcontaining chemotherapy. This may be moderate to severe and has been associated with death.<\/p><p>When patients are candidates for treatment with Teotaxol\u00ae in combination with trastuzumab, they should undergo baseline cardiac assessment. Cardiac function should be further monitored during treatment (e.g. every three months) to help identify patients who may develop cardiac dysfunction. For more details see summary of product characteristics of trastuzumab.<\/p><p>Ventricular arrhythmia including ventricular tachycardia (sometimes fatal) has been reported in patients treated with Teotaxol\u00ae in combination regimens including doxorubicin, 5\u00adfluorouracil and\/ or cyclophosphamide. Baseline cardiac assessment is recommended.<\/p><p><strong>Eye disorders<\/strong><\/p><p>Cystoid macular oedema (CMO) has been reported in patients treated with docetaxel. Patients with impaired vision should undergo a prompt and complete ophthalmologic examination. In case CMO is diagnosed, Teotaxol\u00ae treatment should be discontinued and appropriate treatment initiated.<\/p><p><strong>Second primary malignancies<\/strong><\/p><p>Second primary malignancies have been reported when docetaxel was given in combination with anticancer treatments known to be associated with second primary malignancies. (Including acute myeloid leukaemia, myelodysplastic syndrome and non\u00adHodgkin lymphoma) may occur several months or years after Teotaxol\u00ae containing therapy. Patients should be monitored for second primary malignancies.<\/p><p><strong>Tumour Lysis Syndrome<\/strong><\/p><p>Tumour lysis syndrome has been reported with docetaxel after the first or the second cycle. Patients at risk of tumour lysis syndrome (e.g. with renal impairment, hyperuricemia, bulky tumour, rapid progression) should be closely monitored. Correction of dehydration and treatment of high uric acid levels are recommended prior to initiation of treatment.<\/p><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<span class=\"item-divider\" aria-hidden=\"true\"><\/span>\n\t\t\t\t\t\t\t<div class=\"the7-e-tab-item-wrapper\" data-tab=\"4\">\n\t\t\t\t\t<div class=\"the7-e-tab-title\" aria-selected=\"false\" data-tab=\"4\" role=\"tab\" tabindex=\"-1\" aria-controls=\"elementor-tab-content-1774\" aria-expanded=\"false\">\n\t\t\t\t\t\t\t\t\t<span class=\"the7-e-tab-icon elementor-icon\" aria-hidden=\"true\"><i class=\"fas fa-list-ul\"><\/i><\/span>\n\t\t\t\t\t\t\t\t\t<h5 class=\"the7-e-tab-title-text\">\n\t\t\t\t\t\t\tDosage & Administration\t\t\t\t\t\t<\/h5>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t<div id=\"the7-e-tab-content-1774\" class=\"the7-e-tab-content the7-e-tab-text-content\" data-tab=\"4\" role=\"tabpanel\" aria-labelledby=\"the7-e-tab-title-1774\" tabindex=\"0\" hidden=\"hidden\"><p>Administration of Teotaxol\u00ae should be in a facility equipped under the supervision of qualified physician to manage possible complications (e.g., anaphylaxis). Teotaxol\u00ae administration is intravenously (IV) over one-hour every 3 weeks. For all indications, dose adjustment due to toxicities should be considered as needed.<\/p><ul><li><strong>Dosage:<\/strong><ul><li><strong>Breast Cancer<\/strong><\/li><li>For locally advanced or metastatic breast cancer after failure of prior chemotherapy, the recommended dose of Teotaxol\u00ae is 60 mg\/m<sup>2<\/sup> to 100 mg\/m<sup>2 <\/sup>administered intravenously over 1 hour every 3 weeks.<\/li><li>For the adjuvant treatment of operable node-positive breast cancer, the recommended Teotaxol\u00ae dose is 75 mg\/m<sup>2<\/sup> administered 1 hour after doxorubicin 50 mg\/m<sup>2<\/sup> and cyclophosphamide 500 mg\/m<sup>2<\/sup> every 3 weeks for 6 courses. Prophylactic G-CSF may be used to mitigate the risk of hematological toxicities.<\/li><li>In combination with trastuzumab the recommended dose of Teotaxol\u00ae is 100 mg\/m every three weeks, with trastuzumab administered weekly.<\/li><li>In combination with capecitabine, the recommended dose of Teotaxol\u00ae is 75 mg\/m every three weeks, with capecitabine administered for 2 weeks followed by a 1\u00adweek rest period.<\/li><li><strong>Non-Small Cell Lung Cancer<\/strong><\/li><li>For chemotherapy-na\u00efve patients, Teotaxol\u00ae was evaluated in combination with cisplatin. The recommended dose of Teotaxol\u00ae is 75 mg\/m<sup>2 <\/sup>administered intravenously over 1 hour immediately followed by cisplatin 75 mg\/m<sup>2<\/sup> over 30-60 minutes every 3 weeks.<\/li><li>For treatment after failure of prior platinum-based chemotherapy, Teotaxol\u00ae was evaluated as monotherapy, and the recommended dose is 75 mg\/m<sup>2<\/sup> administered intravenously over 1 hour every 3 weeks. A dose of 100 mg\/m<sup>2<\/sup> in patients previously treated with chemotherapy was associated with increased hematologic toxicity, infection, and treatment-related mortality in randomized, controlled trials<em>.<\/em><\/li><li><strong>Prostate cancer<\/strong><\/li><li>For Metastatic hormone\u00adsensitive prostate cancer, the recommended dose of Teotaxol\u00ae is 75 mg\/m<sup>2<\/sup> every 3 weeks as a 1-hour intravenous infusion for 6 cycles. Prednisone 5 mg orally twice daily is administered continuously.<\/li><li>For Metastatic castration\u00adresistant prostate cancer, the recommended dose of Teotaxol\u00ae is 75 mg\/m<sup>2<\/sup>. Prednisone 5 mg orally twice daily is administered continuously.<\/li><li><strong>Gastric adenocarcinoma<\/strong><\/li><li>For gastric adenocarcinoma, the recommended dose of Teotaxol\u00ae is 75 mg\/m<sup>2<\/sup> as a 1-hour intravenous infusion, followed by cisplatin 75 mg\/m<sup>2<\/sup>, as a 1 to 3 hour intravenous infusion (both on day 1 only), followed by fluorouracil 750 mg\/m<sup>2<\/sup> per day given as a 24-hour continuous intravenous infusion for 5 days, starting at the end of the cisplatin infusion. Treatment is repeated every three weeks. Patients must receive premedication with antiemetics and appropriate hydration for cisplatin administration.<\/li><li><strong>Head and Neck Cancer<\/strong><\/li><\/ul><\/li><\/ul><p>Patients must receive premedication with antiemetics, and appropriate hydration (prior to and after cisplatin administration). Prophylaxis for neutropenic infections should be administered. All patients treated on the docetaxel containing arms of the TAX323 and TAX324 studies received prophylactic antibiotics.<\/p><ul><li><em>In Induction chemotherapy followed by radiotherapy (TAX323)<\/em>, For the induction treatment of locally advanced inoperable SCCHN, the recommended dose of Teotaxol\u00ae is 75 mg\/m<sup>2<\/sup> as a 1 hour intravenous infusion followed by cisplatin 75 mg\/m<sup>2<\/sup> intravenously over 1 hour, on day one, followed by fluorouracil as a continuous intravenous infusion at 750 mg\/m<sup>2<\/sup> per day for five days. This regimen is administered every 3 weeks for 4 cycles. Following chemotherapy, patients should receive radiotherapy.<\/li><li><em>In Induction chemotherapy followed by chemoradiotherapy (TAX324)<\/em>, For the induction treatment of patients with locally advanced (unresectable, low surgical cure, or organ preservation) SCCHN, the recommended dose of Teotaxol\u00ae is 75 mg\/m<sup>2<\/sup> as a 1 hour intravenous infusion on day 1, followed by cisplatin 100 mg\/m<sup>2<\/sup> administered as a 30-minute to 3 hour infusion, followed by fluorouracil 1000 mg\/m<sup>2<\/sup>\/day as a continuous infusion from day 1 to day 4. This regimen is administered every 3 weeks for 3 cycles. Following chemotherapy, patients should receive chemoradiotherapy.<\/li><li><strong>Premedication Regimen<\/strong><\/li><\/ul><p>All patients should be premedicated with oral corticosteroids (see below for prostate cancer) such as dexamethasone 16 mg per day (e.g., 8 mg twice daily) for 3 days starting 1 day prior to Teotaxol\u00ae administration in order to reduce the incidence and severity of fluid retention as well as the severity of hypersensitivity reactions.<\/p><p>For hormone-refractory metastatic prostate cancer, given the concurrent use of prednisone, the recommended premedication regimen is oral dexamethasone 8 mg, at 12 hours, 3 hours and 1 hour before the Teotaxol\u00ae infusion.<\/p><ul><li><strong>Dose Adjustment during treatment:<\/strong><\/li><\/ul><p>Teotaxol\u00ae should be administered when the neutrophil count is \u2265 1,500 cells\/mm<sup>3<\/sup>. In patients who experienced either febrile neutropenia, neutrophil count &lt; 500 cells\/mm<sup>3<\/sup> for more than one week, severe or cumulative cutaneous reactions or severe peripheral neuropathy during Teotaxol\u00ae therapy, the dose of Teotaxol\u00ae should be reduced from 100 mg\/m<sup>2<\/sup> to 75 mg\/m<sup>2<\/sup> and\/or from 75 to 60 mg\/m<sup>2<\/sup>. If the patient continues to experience these reactions at 60 mg\/m<sup>2<\/sup>, the treatment should be discontinued. Conversely, patients who are dosed initially at 60 mg\/m<sup>2<\/sup> and who do not experience febrile neutropenia, neutrophils &lt;500 cells\/mm<sup>3<\/sup> for more than 1 week, severe or cumulative cutaneous reactions, or severe peripheral neuropathy during Teotaxol\u00ae therapy may tolerate higher doses. Patients who develop \u2265grade 3 peripheral neuropathy should have Teotaxol\u00ae treatment discontinued entirely.<\/p><ul><li><strong>Breast Cancer<\/strong><\/li><\/ul><p>Teotaxol\u00ae in combination with doxorubicin and cyclophosphamide should be administered when the neutrophil count is \u22651,500 cells\/mm<sup>3<\/sup>. Patients who experience febrile neutropenia should receive G-CSF in all subsequent cycles. Patients who continue to experience this reaction should remain on G-CSF and have their Teotaxol\u00ae dose reduced to 60 mg\/m<sup>2<\/sup>. Patients who experience grade 3 or 4 stomatitis should have their Teotaxol\u00ae dose decreased to 60 mg\/m<sup>2<\/sup>. Patients who experience severe or cumulative cutaneous reactions or moderate neurosensory signs and\/or symptoms during Teotaxol\u00ae therapy should have their dosage of Teotaxol\u00ae reduced from 75 to 60 mg\/m<sup>2<\/sup>. If the patient continues to experience these reactions at 60 mg\/m<sup>2<\/sup>, treatment should be discontinued.<\/p><ul><li><strong>Non-Small Cell Lung Cancer<\/strong><\/li><li>For monotherapy with Teotaxol\u00ae treatment after failure of prior platinum-based chemotherapy, patients who are dosed initially at 75 mg\/m<sup>2<\/sup> and who experience either febrile neutropenia, neutrophils&lt;500 cells\/mm<sup>3<\/sup> for more than one week, severe or cumulative cutaneous reactions, or other grade 3\/4 non-hematological toxicities during Teotaxol\u00ae treatment should have treatment withheld until resolution of the toxicity and then resumed at 55 mg\/m<sup>2<\/sup>. Patients who develop \u2265grade 3 peripheral neuropathy should have Teotaxol\u00ae treatment discontinued entirely.<\/li><li>For combination therapy with Teotaxol\u00ae for chemotherapy-na\u00efve NSCLC, in patients who are dosed initially at Teotaxol\u00ae 75 mg\/m<sup>2<\/sup> in combination with cisplatin, and whose nadir of platelet count during the previous course of therapy is &lt;25,000 cells\/mm<sup>3<\/sup>, in patients who experience febrile neutropenia, and in patients with serious non-hematologic toxicities, the Teotaxol\u00ae dosage in subsequent cycles should be reduced to 65 mg\/m<sup>2<\/sup>. In patients who require a further dose reduction, a dose of 50 mg\/m<sup>2<\/sup> is recommended. For cisplatin dosage adjustments, see manufacturers&#8217; prescribing information.<\/li><li><strong>Prostate Cancer<\/strong><\/li><li>For combination therapy with Teotaxol\u00ae for hormone-refractory metastatic prostate cancer, Teotaxol\u00ae should be administered when the neutrophil count is \u22651,500 cells\/mm<sup>3<\/sup>. Patients who experience either febrile neutropenia, neutrophils&lt; 500cells\/mm<sup>3<\/sup> for more than one week, severe or cumulative cutaneous reactions or moderate neurosensory signs and\/or symptoms during Teotaxol\u00ae therapy should have the dosage of Teotaxol\u00ae reduced from 75 to 60 mg\/m<sup>2<\/sup>. If the patient continues to experience these reactions at 60 mg\/m<sup>2<\/sup>, the treatment should be discontinued.<\/li><li><strong>Gastric or Head and Neck Cancer<\/strong><\/li><li>For Teotaxol\u00ae in combination with cisplatin and fluorouracil in gastric cancer or head and neck cancer, Patients treated with Teotaxol\u00ae in combination with cisplatin and fluorouracil must receive antiemetics and appropriate hydration according to current institutional guidelines. In both studies, G-CSF was recommended during the second and\/or subsequent cycles in case of febrile neutropenia, or documented infection with neutropenia, or neutropenia lasting more than 7 days. If an episode of febrile neutropenia, prolonged neutropenia or neutropenic infection occurs despite G-CSF use, the Teotaxol\u00ae dose should be reduced from 75 mg\/m<sup>2<\/sup> to 60 mg\/m<sup>2<\/sup>. If subsequent episodes of complicated neutropenia occur the Teotaxol\u00ae dose should be reduced from 60 mg\/m<sup>2<\/sup> to 45 mg\/m<sup>2<\/sup>. In case of grade 4 thrombocytopenia the Teotaxol\u00ae dose should be reduced from 75 mg\/m<sup>2<\/sup> to 60 mg\/m<sup>2<\/sup>. Patients should not be retreated with subsequent cycles of Teotaxol\u00ae until neutrophils recover to a level &gt;1,500 cells\/mm<sup>3<\/sup> and platelets recover to a level &gt;100,000 cells\/mm<sup>3<\/sup>. Discontinue treatment if these toxicities persist.<\/li><\/ul><ul><li>Recommended dose modifications for toxicities in patients treated with Teotaxol\u00ae in combination with cisplatin and fluorouracil are shown in Table 1.<\/li><\/ul><p><strong>Table 1- Recommended Dose Modifications for Toxicities in Patients Treated with Teotaxol\u00ae in Combination with Cisplatin and Fluorouracil<\/strong><\/p><table><tbody><tr><td width=\"197\"><p><strong>Toxicity<\/strong><\/p><\/td><td width=\"391\"><p><strong>Dosage Adjustment<\/strong><\/p><\/td><\/tr><tr><td width=\"197\"><p>Diarrhea grade 3<\/p><\/td><td width=\"391\"><p>First episode: reduce fluorouracil dose by 20%. Second episode: then reduce Teotaxol\u00ae dose by 20%.<\/p><\/td><\/tr><tr><td width=\"197\"><p>Diarrhea grade 4<\/p><\/td><td width=\"391\"><p>First episode: reduce Teotaxol\u00ae and fluorouracil doses by 20%.<\/p><p>Second episode: discontinue treatment.<\/p><\/td><\/tr><tr><td width=\"197\"><p>Stomatitis\/mucositis grade 3<\/p><\/td><td width=\"391\"><p>First episode: reduce fluorouracil dose by 20%. Second episode: stop fluorouracil only, at all subsequent cycles.<\/p><p>Third episode: reduce Teotaxol\u00ae dose by 20%.<\/p><\/td><\/tr><tr><td width=\"197\"><p>Stomatitis\/mucositis grade 4<\/p><\/td><td width=\"391\"><p>First episode: stop fluorouracil only, at all subsequent cycles. Second episode: reduce Teotaxol\u00ae dose by 20%.<\/p><\/td><\/tr><\/tbody><\/table><p><strong>\u00a0<\/strong><\/p><ul><li>Liver Dysfunction:<\/li><\/ul><p>In case of AST\/ALT &gt;2.5 to \u22645 x ULN and AP \u22642.5 x ULN, or AST\/ALT &gt;1.5 to \u22645 x ULN and AP &gt;2.5 to \u22645 x ULN, Teotaxol\u00ae should be reduced by 20%.<\/p><p>In case of AST\/ALT &gt;5 x ULN and\/or AP &gt;5 x ULN Teotaxol\u00ae should be stopped.<\/p><p>The dose modifications for cisplatin and fluorouracil in the gastric cancer study are<\/p><p>provided below:<\/p><p>Cisplatin dose modifications and delays<\/p><p>Peripheral neuropathy: A neurological examination should be performed before entry<\/p><p>into the study, and then at least every 2 cycles and at the end of treatment. In the case of<\/p><p>neurological signs or symptoms, more frequent examinations should be performed and<\/p><p>the following dose modifications can be made according to NCIC-CTC grade:<\/p><ul><li>Grade 2: Reduce cisplatin dose by 20%.<\/li><li>Grade 3: Discontinue treatment.<\/li><\/ul><p>Ototoxicity: In the case of grade 3 toxicity, discontinue treatment.<\/p><p>Nephrotoxicity: In the event of a rise in serum creatinine \u2265grade 2 (&gt;1.5 x normal value)<\/p><p>despite adequate rehydration, CrCl should be determined before each subsequent cycle and<\/p><p>the following dose reductions should be considered (see Table 2).<\/p><p><strong>Table 2 \u2013 Dose Reductions for Evaluation of Creatinine Clearance<\/strong><\/p><table><tbody><tr><td width=\"301\"><p><strong>Creatinine clearance result<\/strong><strong><br \/><\/strong><strong>before next cycle<\/strong><\/p><\/td><td width=\"301\"><p><strong>Cisplatin dose next cycle<\/strong><\/p><\/td><\/tr><tr><td width=\"301\"><p>CrCl \u226560 mL\/min<\/p><\/td><td width=\"301\"><p>Full dose of cisplatin was given. CrCl was to be repeated<br \/>before each treatment cycle.<\/p><\/td><\/tr><tr><td width=\"301\"><p>CrCl between 40 and 59<br \/>mL\/min<\/p><\/td><td width=\"301\"><p>Dose of cisplatin was reduced by 50% at subsequent<br \/>cycle. If CrCl was &gt;60 mL\/min at end of cycle, full<br \/>cisplatin dose was reinstituted at the next cycle.<br \/>If no recovery was observed, then cisplatin was omitted<br \/>from the next treatment cycle.<\/p><\/td><\/tr><tr><td width=\"301\"><p>CrCl &lt;40 mL\/min<\/p><\/td><td width=\"301\"><p>Dose of cisplatin was omitted in that treatment cycle only.<br \/>If CrCl was still &lt;40 mL\/min at the end of cycle, cisplatin<br \/>was discontinued.<br \/>If CrCl was &gt;40 and &lt;60 mL\/min at end of cycle, a 50%<br \/>cisplatin dose was given at the next cycle.<br \/>If CrCl was &gt;60 mL\/min at end of cycle, full cisplatin<br \/>dose was given at next cycle<\/p><\/td><\/tr><\/tbody><\/table><p>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 CrCl = Creatinine clearance<\/p><p><u>Fluorouracil dose modifications and treatment delays<\/u><br \/>For diarrhea and stomatitis, see <strong>Table 1.<\/strong><strong><br \/><\/strong>In the event of grade 2 or greater plantar-palmar toxicity, fluorouracil should be stopped<br \/>until recovery. The fluorouracil dosage should be reduced by 20%.<br \/>For other greater than grade 3 toxicities, except alopecia and anemia, chemotherapy should<br \/>be delayed (for a maximum of 2 weeks from the planned date of infusion) until resolution<br \/>to grade \u22641 and then recommenced, if medically appropriate.<br \/>For other fluorouracil dosage adjustments, also refer to the manufacturers&#8217; prescribing<br \/>information.<\/p><ul><li>Combination Therapy with Strong CYP3A4 inhibitors:<\/li><\/ul><p>Avoid using concomitant strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin and voriconazole). There are no clinical data with a dose adjustment in patients receiving strong CYP3A4 inhibitors. Based on extrapolation from a pharmacokinetic study with ketoconazole in 7 patients, consider a 50% Teotaxol\u00ae dose reduction if patients require co- administration of a strong CYP3A4 inhibitor.<\/p><ul><li><strong>Administration Precautions:<\/strong><\/li><\/ul><p>Teotaxol\u00ae is a cytotoxic anticancer drug and, as with other potentially toxic compounds, caution should be exercised when handling and preparing Teotaxol\u00ae solutions. The use of gloves is recommended.<\/p><p>If Teotaxol\u00ae or diluted solution for intravenous infusion should come into contact with the skin, immediately and thoroughly wash with soap and water. If Teotaxol\u00ae or diluted solution for intravenous infusion should come into contact with mucosa, immediately and thoroughly wash with soap and water.<\/p><p>Contact of the Teotaxol\u00ae with plasticized PVC equipment or devices used to prepare solutions for infusion is not recommended. In order to minimize patient exposure to the plasticizer DEHP (di-2-ethylhexyl phthalate), which may be leached from PVC infusion bags or sets, the final Teotaxol\u00ae dilution for infusion should be stored in bottles (glass, polypropylene) or plastic bags (polypropylene, polyolefin) and administered through polyethylene-lined administration sets.<\/p><ul><li><strong>Preparation and Administration:<\/strong><\/li><\/ul><p><strong><u>Teotaxol\u00ae 20 mg\/ml concentrate for solution for infusion requires NO prior dilution with a solvent and is ready to add to the infusion solution. <\/u><\/strong><\/p><p>-Each vial is of single use and should be used immediately.<\/p><p>-Allow the required number of boxes of Teotaxol\u00ae concentrate for solution for infusion to stand below 25\u00b0C for 5 minutes before use.<\/p><p>&#8211; Using only a 21-gauge needle, aseptically withdraw the required amount of Teotaxol\u00ae (20 mg docetaxel\/mL) with a calibrated syringe and inject via a single injection (one shot) into a 250 mL infusion bag or bottle of either 0.9% Sodium Chloride solution or 5% Dextrose solution to produce a final concentration of 0.3 mg\/mL to 0.74 mg\/ml. If a dose greater than 200 mg of Teotaxol\u00ae is required, use a larger volume of the infusion vehicle so that a concentration of 0.74 mg\/ml Teotaxol\u00ae is not exceeded.<\/p><p>&#8211; TEOTAXOL\u00ae is compatible and Stable in D5W, LR, NS<\/p><p>&#8211; TEOTAXOL\u00ae is Incompatible with Amphotericin B, doxorubicin liposome, methylprednisolone sodium succinate, nalbuphine<\/p><p>&#8211; Thoroughly mix the infusion by gentle manual rotation and avoid foaming.<\/p><p>&#8211; As with all parenteral products, TEOTAXOL\u00ae should be inspected visually for particulate matter or discoloration prior to administration whenever the solution and container permit. If the TEOTAXOL\u00ae or diluted solution is not clear or appears to have precipitation, it should be discarded.<\/p><p>&#8211; TEOTAXOL\u00ae infusion solution is supersaturated, therefore may crystallize over time. If crystals appear, the solution must no longer be used and shall be discarded.<\/p><p>&#8211; The TEOTAXOL\u00ae diluted solution for infusion should be administered intravenously as a 1-hour infusion under ambient room temperature (below 30\u00b0C) and lighting conditions.<\/p><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<span class=\"item-divider\" aria-hidden=\"true\"><\/span>\n\t\t\t\t\t\t\t<div class=\"the7-e-tab-item-wrapper\" data-tab=\"5\">\n\t\t\t\t\t<div class=\"the7-e-tab-title\" aria-selected=\"false\" data-tab=\"5\" role=\"tab\" tabindex=\"-1\" aria-controls=\"elementor-tab-content-1775\" aria-expanded=\"false\">\n\t\t\t\t\t\t\t\t\t<span class=\"the7-e-tab-icon elementor-icon\" aria-hidden=\"true\"><i class=\"far fa-bell\"><\/i><\/span>\n\t\t\t\t\t\t\t\t\t<h5 class=\"the7-e-tab-title-text\">\n\t\t\t\t\t\t\tAdverse Reactions\t\t\t\t\t\t<\/h5>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t<div id=\"the7-e-tab-content-1775\" class=\"the7-e-tab-content the7-e-tab-text-content\" data-tab=\"5\" role=\"tabpanel\" aria-labelledby=\"the7-e-tab-title-1775\" tabindex=\"0\" hidden=\"hidden\"><ul><li><strong>&gt;10%:<\/strong><\/li><\/ul><p><u>Dermatologic:<\/u> Alopecia (56% to 76%, can be permanent), dermatological reaction (20% to 48%; severe dermatological reaction: 5%), nail disease (11% to 41%)<\/p><p><u>Endocrine &amp; metabolic:<\/u> Fluid retention (26% to 60%)<\/p><p><u>Gastrointestinal:<\/u> Diarrhea (23% to 43%; severe diarrhea: \u22646%), nausea (34% to 42%; severe nausea: \u22645%), stomatitis (19% to 53%; grades 3\/4: 2%), vomiting (22% to 23%; severe vomiting: \u22645%)<\/p><p><u>Hematologic &amp; oncologic:<\/u> Anemia (65% to 97%; grades 3\/4: 8% to 9%), febrile neutropenia (5% to 14%), leukopenia (84% to 99%; grades 3\/4: 49%; grade 4: 32% to 44%), neutropenia (84% to 99%; grades 3\/4: 65%; grade 4: 75% to 86%; nadir [median]: 7 days, duration [severe neutropenia]: 7 days), thrombocytopenia (7% to 14%; grades 3\/4: 3%; grade 4: 1%)<\/p><p><u>Hepatic:<\/u> Increased serum alanine aminotransferase (\u226419%), increased aspartate aminotransferase (\u226419%)<\/p><p><u>Hypersensitivity:<\/u> Hypersensitivity reaction (6% to 21%, including back pain, chest tightness, chills, drug fever, dyspnea, flushing, skin rash; severe hypersensitivity reaction: 3% to 4%)<\/p><p><u>Infection:<\/u> Infection (1% to 34%; severe infection: 2% to 6%)<\/p><p><u>Nervous system:<\/u> Central nervous system toxicity (20% to 58%; including dysesthesia: \u22646%, paresthesia: \u22646%)<\/p><p><u>Neuromuscular &amp; skeletal:<\/u> Asthenia (53% to 66%; severe weakness: 13% to 18%), myalgia (3% to 23%; severe myalgia: 2%), neuromuscular reaction (16%)<\/p><p><u>Respiratory:<\/u> Pulmonary disease (41%)<\/p><p><u>Miscellaneous:<\/u> Fever (31% to 35%)<\/p><ul><li><strong> 1-10%:<\/strong><\/li><\/ul><p><u>Cardiovascular:<\/u> Hypotension (3%)<\/p><p><u>Gastrointestinal:<\/u> Dysgeusia (6%)<\/p><p><u>Hepatic:<\/u> Increased serum alkaline phosphatase (7%), increased serum bilirubin (9%)<\/p><p><u>Local:<\/u> Infusion site reaction (4%; including erythema at injection site, exfoliation of skin, inflammation at injection site, injection site extravasation, local dryness of skin, skin discoloration at injection site, swelling at injection site [vein])<\/p><p><u>Nervous system:<\/u> Peripheral motor neuropathy (4%; severe; mainly distal extremity weakness)<\/p><p><u>Neuromuscular and skeletal:<\/u> Arthralgia (3% to 9%)<\/p><ul><li><strong> &lt;1%:<\/strong><\/li><\/ul><p><u>Dermatologic:<\/u> Onycholysis<\/p><ul><li><strong>Frequency not defined:<\/strong><\/li><\/ul><p><u>Cardiovascular:<\/u> Decreased left ventricular ejection fraction, localized phlebitis<\/p><p><u>Dermatologic:<\/u> Localized erythema of the extremities, nail depigmentation, nail hyperpigmentation<\/p><p><u>Nervous system:<\/u> Fatigue<\/p><p><strong><em><u>Reporting of suspected adverse reactions<\/u><\/em><\/strong><\/p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit\/risk balance of the medicinal product. Please report any adverse drug reactions via contacting Cedal Nano.<\/p><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<span class=\"item-divider\" aria-hidden=\"true\"><\/span>\n\t\t\t\t\t\t\t<div class=\"the7-e-tab-item-wrapper\" data-tab=\"6\">\n\t\t\t\t\t<div class=\"the7-e-tab-title\" aria-selected=\"false\" data-tab=\"6\" role=\"tab\" tabindex=\"-1\" aria-controls=\"elementor-tab-content-1776\" aria-expanded=\"false\">\n\t\t\t\t\t\t\t\t\t<span class=\"the7-e-tab-icon elementor-icon\" aria-hidden=\"true\"><i class=\"fab fa-confluence\"><\/i><\/span>\n\t\t\t\t\t\t\t\t\t<h5 class=\"the7-e-tab-title-text\">\n\t\t\t\t\t\t\tDrug Interactions\t\t\t\t\t\t<\/h5>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t<div id=\"the7-e-tab-content-1776\" class=\"the7-e-tab-content the7-e-tab-text-content\" data-tab=\"6\" role=\"tabpanel\" aria-labelledby=\"the7-e-tab-title-1776\" tabindex=\"0\" hidden=\"hidden\"><p>Drug interactions are divided into three different categories.<\/p><ul><li><strong>Risk C: Monitor Therapy<\/strong><\/li><\/ul><p>Brincidofovir, Chloramphenicol (Ophthalmic), Clofazimine, Clozapine, COVID-19 Vaccine (Adenovirus vector or Inactivated virus), CYP3A4 Inhibitors (Moderate), Erdafitinib, Inebilizumab, Ocrelizumab, Ofatumumab, Pidotimod, Pneumococcal Vaccines, Promazine, Sorafenib, Sphingosine 1-Phosphate (S1P) Receptor Modulator<\/p><ul><li><strong> Risk D: Consider Therapy Modification<\/strong><\/li><\/ul><p>Anthracyclines, Coccidioides immitis Skin Test, COVID-19 Vaccine (mRNA), CYP3A4 Inhibitors (Strong), Deferiprone, Denosumab, Dronedarone, Echinacea, Influenza Virus Vaccines, Leflunomide, Lenograstim, Lipegfilgrastim, Palifermin, Platinum Derivatives, Polymethylmethacrylate, Rabies Vaccine, Ropeginterferon Alfa-2b, Sipuleucel-T, Vaccines (Inactivated)<\/p><ul><li><strong> Risk X: Avoid Combination<\/strong><\/li><\/ul><p>\u00a0Abametapir, Baricitinib, BCG, Cladribine, Dengue Tetravalent Vaccine (Live), Dipyrone, Fexinidazole, Fusidic Acid (Systemic), Natalizumab, Pimecrolimus, Poliovirus Vaccine (Live\/Trivalent\/Oral), Rubella- or Varicella-Containing Live Vaccines, Ruxolitinib (Topical), Tacrolimus (Topical), Talimogene Laherparepvec, Tertomotide, Tofacitinib, Typhoid Vaccine, Upadacitinib, Vaccines (Live), Yellow Fever Vaccine<\/p><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<span class=\"item-divider\" aria-hidden=\"true\"><\/span>\n\t\t\t\t\t\t\t<div class=\"the7-e-tab-item-wrapper\" data-tab=\"7\">\n\t\t\t\t\t<div class=\"the7-e-tab-title\" aria-selected=\"false\" data-tab=\"7\" role=\"tab\" tabindex=\"-1\" aria-controls=\"elementor-tab-content-1777\" aria-expanded=\"false\">\n\t\t\t\t\t\t\t\t\t<span class=\"the7-e-tab-icon elementor-icon\" aria-hidden=\"true\"><i class=\"fas fa-baby\"><\/i><\/span>\n\t\t\t\t\t\t\t\t\t<h5 class=\"the7-e-tab-title-text\">\n\t\t\t\t\t\t\t Pregnancy and Lactation\t\t\t\t\t\t<\/h5>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t<div id=\"the7-e-tab-content-1777\" class=\"the7-e-tab-content the7-e-tab-text-content\" data-tab=\"7\" role=\"tabpanel\" aria-labelledby=\"the7-e-tab-title-1777\" tabindex=\"0\" hidden=\"hidden\"><p><strong>Pregnancy<\/strong><\/p><p><strong>Pregnancy Category: D<\/strong><\/p><p>Based on its mechanism of action and findings in animals, Teotaxol\u00ae can cause fetal harm when administered to a pregnant woman. Formulation contain alcohol, which is also associated with adverse fetal effects.<\/p><p>If Teotaxol\u00ae is used during pregnancy, or if the patient becomes pregnant while receiving this drug, the patient should be apprised of the potential hazard to the fetus. Women of childbearing potential should be advised to avoid becoming pregnant during therapy with Teotaxol\u00ae.<\/p><p><strong>Breast feeding<\/strong><\/p><p>Teotaxol\u00ae is a lipophilic substance but it is not known whether it is excreted in human milk. Consequently, because of the potential for adverse reactions in nursing infants, is not recommended by the manufacturer during treatment and for 1 week after the last Teotaxol\u00ae dose.<\/p><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<span class=\"item-divider\" aria-hidden=\"true\"><\/span>\n\t\t\t\t\t\t\t<div class=\"the7-e-tab-item-wrapper\" data-tab=\"8\">\n\t\t\t\t\t<div class=\"the7-e-tab-title\" aria-selected=\"false\" data-tab=\"8\" role=\"tab\" tabindex=\"-1\" aria-controls=\"elementor-tab-content-1778\" aria-expanded=\"false\">\n\t\t\t\t\t\t\t\t\t<span class=\"the7-e-tab-icon elementor-icon\" aria-hidden=\"true\"><i class=\"fas fa-box\"><\/i><\/span>\n\t\t\t\t\t\t\t\t\t<h5 class=\"the7-e-tab-title-text\">\n\t\t\t\t\t\t\tStorage Conditions\t\t\t\t\t\t<\/h5>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t<div id=\"the7-e-tab-content-1778\" class=\"the7-e-tab-content the7-e-tab-text-content\" data-tab=\"8\" role=\"tabpanel\" aria-labelledby=\"the7-e-tab-title-1778\" tabindex=\"0\" hidden=\"hidden\"><p>&#8211; Keep the medicine in the box until it is consumed.<\/p><p>&#8211; store the medicine at temperatures below 30\u00b0 C and stored away from light and moisture.<\/p><p>&#8211; Keep the medicine out of the reach of children and pets.<\/p><p>&#8211; The product is viscous and transparent and has a yellowish color. Avoid using it if it changes color or if you see particles. After preparation, the product should be clear and free of particles, otherwise do not use it.<\/p><p>&#8211; The solution prepared for injection should be taken immediately. If not used immediately, in-use storage times and conditions are the responsibility of the user and would normally not be longer than 4 hours below 25\u00b0C including the one-hour infusion.<\/p><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<span class=\"item-divider\" aria-hidden=\"true\"><\/span>\n\t\t\t\t\t<\/div>\n\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<section class=\"elementor-section elementor-inner-section elementor-element elementor-element-0ba5f97 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"0ba5f97\" data-element_type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-inner-column elementor-element elementor-element-f15ad0a\" data-id=\"f15ad0a\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-200d2fb icon-box-vertical-align-center elementor-widget__width-auto elementor-hidden-desktop elementor-hidden-tablet elementor-hidden-mobile content-align-left icon-position-left icon-vertical-align-start elementor-widget elementor-widget-the7_icon_box_widget\" data-id=\"200d2fb\" data-element_type=\"widget\" data-widget_type=\"the7_icon_box_widget.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\n\t\t<div class=\"the7-box-wrapper the7-elementor-widget the7_icon_box_widget-200d2fb\">\t\t\t<div class=\"box-content-wrapper\">\n\t\t\t\t\t\t\t\t<div class=\"box-content\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h4 class=\"box-heading\">\n\t\t\t\t\t\t\t<a href=\"\/wp-content\/uploads\/2022\/03\/Docetaxel-English.docx\">\t\t\t\t\t\t\t\tProduct Description File\t\t\t\t\t\t\t<\/a>\t\t\t\t\t\t<\/h4>\n\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-64c2316 elementor-share-buttons--view-icon elementor-share-buttons--skin-minimal elementor-share-buttons--shape-circle elementor-grid-mobile-6 elementor-share-buttons--align-left elementor-share-buttons--color-custom elementor-widget__width-auto elementor-grid-0 elementor-widget elementor-widget-share-buttons\" data-id=\"64c2316\" data-element_type=\"widget\" data-widget_type=\"share-buttons.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<div class=\"elementor-grid\">\n\t\t\t\t\t\t\t\t<div class=\"elementor-grid-item\">\n\t\t\t\t\t\t<div\n\t\t\t\t\t\t\tclass=\"elementor-share-btn elementor-share-btn_twitter\"\n\t\t\t\t\t\t\trole=\"button\"\n\t\t\t\t\t\t\ttabindex=\"0\"\n\t\t\t\t\t\t\taria-label=\"Share on twitter\"\n\t\t\t\t\t\t>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-share-btn__icon\">\n\t\t\t\t\t\t\t\t<i class=\"fab fa-twitter\" aria-hidden=\"true\"><\/i>\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-grid-item\">\n\t\t\t\t\t\t<div\n\t\t\t\t\t\t\tclass=\"elementor-share-btn elementor-share-btn_linkedin\"\n\t\t\t\t\t\t\trole=\"button\"\n\t\t\t\t\t\t\ttabindex=\"0\"\n\t\t\t\t\t\t\taria-label=\"Share on linkedin\"\n\t\t\t\t\t\t>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-share-btn__icon\">\n\t\t\t\t\t\t\t\t<i class=\"fab fa-linkedin\" aria-hidden=\"true\"><\/i>\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-grid-item\">\n\t\t\t\t\t\t<div\n\t\t\t\t\t\t\tclass=\"elementor-share-btn elementor-share-btn_whatsapp\"\n\t\t\t\t\t\t\trole=\"button\"\n\t\t\t\t\t\t\ttabindex=\"0\"\n\t\t\t\t\t\t\taria-label=\"Share on whatsapp\"\n\t\t\t\t\t\t>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-share-btn__icon\">\n\t\t\t\t\t\t\t\t<i class=\"fab fa-whatsapp\" aria-hidden=\"true\"><\/i>\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-grid-item\">\n\t\t\t\t\t\t<div\n\t\t\t\t\t\t\tclass=\"elementor-share-btn elementor-share-btn_telegram\"\n\t\t\t\t\t\t\trole=\"button\"\n\t\t\t\t\t\t\ttabindex=\"0\"\n\t\t\t\t\t\t\taria-label=\"Share on telegram\"\n\t\t\t\t\t\t>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-share-btn__icon\">\n\t\t\t\t\t\t\t\t<i class=\"fab fa-telegram\" aria-hidden=\"true\"><\/i>\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-grid-item\">\n\t\t\t\t\t\t<div\n\t\t\t\t\t\t\tclass=\"elementor-share-btn elementor-share-btn_print\"\n\t\t\t\t\t\t\trole=\"button\"\n\t\t\t\t\t\t\ttabindex=\"0\"\n\t\t\t\t\t\t\taria-label=\"Share on print\"\n\t\t\t\t\t\t>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-share-btn__icon\">\n\t\t\t\t\t\t\t\t<i class=\"fas fa-print\" aria-hidden=\"true\"><\/i>\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>\u0644\u0648\u0631\u0645 \u0627\u06cc\u067e\u0633\u0648\u0645 \u0645\u062a\u0646 \u0633\u0627\u062e\u062a\u06af\u06cc \u0628\u0627 \u062a\u0648\u0644\u06cc\u062f \u0633\u0627\u062f\u06af\u06cc \u0646\u0627\u0645\u0641\u0647\u0648\u0645 \u0627\u0632 \u0635\u0646\u0639\u062a \u0686\u0627\u067e \u0648 \u0628\u0627 \u0627\u0633\u062a\u0641\u0627\u062f\u0647 \u0627\u0632 \u0637\u0631\u0627\u062d\u0627\u0646 \u06af\u0631\u0627\u0641\u06cc\u06a9 \u0627\u0633\u062a.<\/p>\n","protected":false},"author":1,"featured_media":7800,"comment_status":"closed","ping_status":"closed","template":"","dt_portfolio_category":[48],"dt_portfolio_tags":[],"class_list":["post-4028","dt_portfolio","type-dt_portfolio","status-publish","has-post-thumbnail","hentry","dt_portfolio_category-oncology-en"],"_links":{"self":[{"href":"https:\/\/cedalco.com\/en\/wp-json\/wp\/v2\/dt_portfolio\/4028","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cedalco.com\/en\/wp-json\/wp\/v2\/dt_portfolio"}],"about":[{"href":"https:\/\/cedalco.com\/en\/wp-json\/wp\/v2\/types\/dt_portfolio"}],"author":[{"embeddable":true,"href":"https:\/\/cedalco.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cedalco.com\/en\/wp-json\/wp\/v2\/comments?post=4028"}],"version-history":[{"count":42,"href":"https:\/\/cedalco.com\/en\/wp-json\/wp\/v2\/dt_portfolio\/4028\/revisions"}],"predecessor-version":[{"id":12466,"href":"https:\/\/cedalco.com\/en\/wp-json\/wp\/v2\/dt_portfolio\/4028\/revisions\/12466"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cedalco.com\/en\/wp-json\/wp\/v2\/media\/7800"}],"wp:attachment":[{"href":"https:\/\/cedalco.com\/en\/wp-json\/wp\/v2\/media?parent=4028"}],"wp:term":[{"taxonomy":"dt_portfolio_category","embeddable":true,"href":"https:\/\/cedalco.com\/en\/wp-json\/wp\/v2\/dt_portfolio_category?post=4028"},{"taxonomy":"dt_portfolio_tags","embeddable":true,"href":"https:\/\/cedalco.com\/en\/wp-json\/wp\/v2\/dt_portfolio_tags?post=4028"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}